Microbot Medical (NASDAQ:MBOT) Research Coverage Started at B. Riley Securities

B. Riley Securities started coverage on shares of Microbot Medical (NASDAQ:MBOT) in a report released on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $5.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also commented on the company. B. Riley Financial started coverage on Microbot Medical in a research note on Tuesday. They set a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Microbot Medical in a research report on Friday, November 28th. Roth Mkm began coverage on shares of Microbot Medical in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 price target on the stock. Finally, Wall Street Zen lowered shares of Microbot Medical from a “hold” rating to a “sell” rating in a research report on Saturday, October 25th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Microbot Medical Stock Up 4.5%

NASDAQ MBOT opened at $2.09 on Tuesday. Microbot Medical has a twelve month low of $1.25 and a twelve month high of $4.67. The business has a 50-day moving average price of $2.07 and a 200-day moving average price of $2.60. The firm has a market cap of $140.36 million, a price-to-earnings ratio of -4.64 and a beta of 1.28.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Research analysts expect that Microbot Medical will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Cornerstone Advisory LLC purchased a new stake in shares of Microbot Medical in the 3rd quarter worth approximately $30,000. American Century Companies Inc. purchased a new stake in Microbot Medical during the second quarter worth $32,000. Zacks Investment Management purchased a new stake in Microbot Medical during the third quarter worth $33,000. Squarepoint Ops LLC bought a new stake in Microbot Medical during the 3rd quarter valued at $37,000. Finally, Foundations Investment Advisors LLC purchased a new position in shares of Microbot Medical in the 3rd quarter valued at $38,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.